USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Coloplast A/S

USPTO PatentsView assignee record - 581 granted patents across 61 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Coloplast ranks #791 of 49,997 tracked US assignees by granted-patent volume, with 581 patents across 61 technology areas.

#791
of 49,997 US assignees by volume
Top 1%
by Innovation Score (64.9/100)
13.3
avg claims per patent
-25%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R791 · Foreign Corporation #791 · 581 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MID 581 grants
  • TOP-DECILE #791/49,997
  • PHOTO-FINISH University of…
  • CPC-WIDE A61F · 61 areas
  • INNOV-STRONG 64.9/100
  • CLAIMS-RICH 13.3 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DOWN -25% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: University of Central Florida Research Foundation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Coloplast

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Coloplast's Innovation Score is 64.9/100 (top 1% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Coloplast's grant cadence moved

Between 2020–2024, Coloplast A/S received 231 grants versus 310 in 2015–2019 (-25% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2017 at 74 grants and bottomed in 2020 at 31. Lead class A61F accounts for 65.1% of the portfolio across 61 subclasses. Volume neighbours: Children's Medical Center Corporation (#787) and The Government of the United States of America, as represented by the Secretary of the Navy (#795).

Coloplast's three-year grant acceleration

From 2019–2021 to 2022–2024, Coloplast A/S moved from 111 to 165 grants (1.49x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #465. See the growth leaderboard.

Who files at Coloplast's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Coloplast holds 581 patents at rank #791, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Coloplast

By rank, the assignees closest to #791 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Coloplast's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Coloplast, neither rank-band nor same-CPC leaders (those blocks stay above).

Coloplast's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

65 Top 1% higher than 99% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

20304050607080 20152016201720182019202020212022202320242025 40
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Coloplast A/S patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 73 12.6%
2016 57 9.8%
2017 74 12.7%
2018 61 10.5%
2019 45 7.7%
2020 31 5.3%
2021 35 6.0%
2022 45 7.7%
2023 62 10.7%
2024 58 10.0%
2025partial year 40 6.9%

Which technologies does Coloplast A/S patent most?

Top 15 of 61 technology areas

Where it ranks

Overall rank by patents

#791

of 49,997 tracked assignees

Innovation Score

64.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Coloplast A/S's patent record in context - here's where to go next.

  • Coloplast A/S's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 65.1% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #791 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Coloplast A/S against Children's Medical Center Corporation, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 64.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.